Applying the Addictions Neuroclinical Assessment to derive neurofunctional domains in individuals who use methamphetamine.
Applying the Addictions Neuroclinical Assessment to derive neurofunctional domains in individuals who use methamphetamine.
复制标题
DOI：
10.1016/j.bbr.2022.113876
复制
发表时间：
2022-06-03
影响因子：
2.7
通讯作者：
Ray, Lara A.
中科院分区：
文献类型：
--
作者：
Nieto, Steven J.;Ray, Lara A.
关键词：
成瘾神经临床评估（ANA）被提出作为一个神经科学的临床框架，以了解成瘾的异质性，包括三个领域的功能障碍：激励显着性，负性情绪和执行功能。ANA已在酒精领域得到验证，但尚未扩展到其他物质。因此，本研究的目的是复制和扩展ANA框架甲基苯丙胺使用障碍。非寻求治疗的个人（N = 185）谁报告定期使用甲基苯丙胺完成了一个深表型电池，包括自我报告和行为的措施，评估甲基苯丙胺的渴望和情感戒断症状，情绪和焦虑行为学，冒险行为，工作记忆，注意力和冲动。因子分析技术被用于在一个迭代的方式来获得潜在的因素，解释生物行为的变化在样品中。因素得分和甲基苯丙胺使用的人口和临床指标之间的关系进行了检查，以评估潜在因素的结构效度。深层表型结合因子分析技术涉及三个相互关联的神经功能域，映射到拟议的ANA域：激励显着性，负面情绪和执行功能。每个域都与甲基苯丙胺使用的人口统计学和临床指标相关联，为其结构效度提供初步支持。ANA框架有望通过识别神经科学信息表型来解释成瘾的异质性。来自ANA框架的知识可以应用于推进精准医学，并为许多物质使用障碍提供药物开发信息，特别是那些没有批准的药物治疗，如甲基苯丙胺。
The Addictions Neuroclinical Assessment (ANA) was proposed as a neuroscience-informed clinical framework to understand heterogeneity in addiction encompassing dysfunction in three domains: incentive salience, negative emotionality, and executive functions. The ANA has been validated in the alcohol field but has not been extended to other substances. Thus, the objective of the current study was to replicate and extend the ANA framework to methamphetamine use disorder. Non-treatment seeking individuals (N = 185) who reported regular methamphetamine use completed a deep phenotyping battery comprising self-report and behavioral measures that assessed methamphetamine craving and emotional withdrawal symptoms, mood and anxiety symptomatology, risk-taking behaviors, working memory, attention, and impulsivity. Factor analytic techniques were used in an iterative manner to derive latent factors that explained biobehavioral variation in the sample. The relationship between factor scores and demographic and clinical indicators of methamphetamine use were examined to assess the construct validity of the latent factors. Deep phenotyping combined with factor analytic techniques implicated three intercorrelated neurofunctional domains that map on to the proposed ANA domains: incentive salience, negative emotionality, and executive function. Each of the domains were associated with demographic and clinical indicators of methamphetamine use providing initial support for their construct validity. The ANA framework holds promise for explaining heterogeneity in addiction by identifying neuroscience-informed phenotypes. Knowledge from the ANA framework may be applied to advance precision medicine and inform medications development for a host of substance use disorders, particularly those with no approved pharmacotherapy such as methamphetamine.
登录
查看更多内容
影响因子：
3.4
作者：
Bickel, Warren K.;Jarmolowicz, David P.;Mueller, E. Terry;Gatchalian, Kirstin M.;McClure, Samuel M.
通讯作者：
McClure, Samuel M.
影响因子：
3.9
作者：
Hien, DA;Nunes, E;Fraser, D
通讯作者：
Fraser, D
影响因子：
25.8
作者：
Ashok AH;Mizuno Y;Volkow ND;Howes OD
通讯作者：
Howes OD
影响因子：
3.6
作者：
Akindipe, Taiwo;Wilson, Don;Stein, Dan J.
通讯作者：
Stein, Dan J.
影响因子：
5.5
作者：
Hartwell, Emily E.;Moallem, Nathasha R.;Ray, Lara A.
通讯作者：
Ray, Lara A.